Should You Take TMG With NMN?

If you buy NMN, the algorithm will soon suggest you also buy TMG — trimethylglycine, also called betaine — usually with a confident line about "replacing the methyl groups NMN burns through." The pairing has become almost reflexive in longevity circles. The theory behind it is real biochemistry, not nonsense. But the leap from "this could happen" to "you must take TMG or NMN will harm you" is much bigger than the marketing admits, and the human evidence for the stack is thin to absent.

This article separates the mechanism (genuine and worth understanding) from the proof (which, for the specific claim that you need TMG alongside NMN, doesn't really exist in humans). The honest bottom line up front: for most people taking standard NMN doses, TMG is probably optional — a low-risk, low-cost insurance policy with a plausible rationale but no trial showing it's necessary or that it improves how you feel. Neither NMN nor TMG is an FDA-approved drug, and nothing here is a treatment for any condition.

The methyl-drain theory, explained honestly

The argument rests on how your body disposes of excess NAD+ precursors. NMN raises NAD+, and the NAD+ that gets broken down ends up as nicotinamide. To clear nicotinamide, the body methylates it — an enzyme called nicotinamide N-methyltransferase (NNMT) attaches a methyl group to make N1-methylnicotinamide, which is excreted in urine¹². That methyl group comes from S-adenosylmethionine (SAM), the body's universal methyl donor, which is regenerated from methionine through the one-carbon cycle.

So the chain of reasoning is: more NMN → more nicotinamide to clear → more methylation → more SAM consumed → potentially less methyl capacity left for everything else SAM does (DNA methylation, neurotransmitter synthesis, and converting homocysteine back to methionine). If methyl supply gets tight, homocysteine — a sulfur amino acid that rises when methylation is strained — could drift up.

That methylated metabolites of nicotinamide are real and measurable is not in doubt: a pilot study tracking the human NAD+ metabolome during an NAD infusion found methylated nicotinamide products rising and appearing in urine, confirming that clearing an NAD+ load does draw on methylation⁴. And one animal study found that high-dose nicotinamide supplementation in developing rats produced detrimental metabolic and epigenetic (methylation-related) changes — a genuine signal that a large nicotinamide load can perturb methylation, at least in rodents at high doses⁵. So the theory has legitimate roots.

Where TMG comes in — and the gap in the logic

TMG (trimethylglycine/betaine) is itself a methyl donor. Through the betaine-homocysteine methyltransferase pathway, betaine donates a methyl group to convert homocysteine back to methionine — directly topping up the methyl economy and lowering homocysteine. This is well established in humans: oral betaine acutely and dose-dependently lowers plasma homocysteine in healthy people⁷, an effect confirmed under both fasting and methionine-load conditions⁶, and betaine status is a known determinant of how high your fasting homocysteine sits⁸⁹. So TMG genuinely does what the stack wants it to do: supply methyl groups and keep homocysteine down.

Here's the gap, though. Every link in the worry-chain is established except the one that actually matters for this stack: there is no human trial showing that NMN, at the doses people take, meaningfully depletes methyl groups or raises homocysteine — and therefore none showing that adding TMG corrects a problem NMN created. The NMN human trials that measured safety and clinical parameters did not report methylation distress or homocysteine spikes as a characteristic finding. In the dose-ranging randomized NMN trial in healthy middle-aged adults, NMN raised NAD+ and was well tolerated across doses¹; single-dose and longer safety studies in men and women similarly found NMN was metabolized without the kind of adverse signal the methyl-drain theory would predict²³. The TMG rationale is extrapolated from mechanism and high-dose animal data, not demonstrated as a real-world deficiency in NMN users.

What the evidence actually supports

Putting the pieces together honestly:

• •The methylation cost of clearing nicotinamide is real — methylated nicotinamide metabolites are measurable in humans⁴, and a heavy nicotinamide load perturbed methylation in rodents⁵.
• •TMG reliably lowers homocysteine and supplies methyl groups — this is solid human pharmacology, repeated across trials⁶⁷⁸⁹.
• •But the specific claim — that NMN doses cause a methyl deficit that TMG must rescue — has no human trial behind it. It's a plausible hypothesis, not a measured effect. The NMN safety trials didn't flag it¹²³.

That's the gap between "could" and "does." TMG fixes a problem that is theoretically possible but hasn't been shown to occur in people taking ordinary NMN doses.

The case for taking it anyway (and the case against)

Reasons it's reasonable to add TMG: it's cheap, it has a coherent mechanism, and it independently lowers homocysteine — which is itself associated with cardiovascular risk in observational data, so a modest reduction isn't a bad thing to have. If you're stacking high-dose NMN or NR, or you already know your homocysteine runs high, TMG is a sensible, low-risk hedge. Think of it as inexpensive insurance against a plausible-but-unproven concern.

Reasons it may be unnecessary — or even worth a second look: for someone on a standard NMN dose with a varied diet (which already supplies betaine, choline, folate, and B12 to run the methyl cycle), the theoretical drain may simply not be large enough to matter. And TMG is not perfectly free of tradeoffs: pooled randomized data found that homocysteine-lowering with betaine raised LDL and total cholesterol in healthy people¹⁰, and a long-term betaine trial echoed an unfavorable lipid signal¹¹. That doesn't make TMG dangerous, but it does puncture the idea that it's an unambiguous "just take it, it can only help" addition. There is a real, if small, lipid tradeoff.

How to think about it

If you want a simple, evidence-anchored framework:

• •On a standard NMN dose (roughly 250–600 mg/day) with a normal diet? TMG is probably optional. The methyl-drain concern is theoretical at those doses, and your diet plus folate/B12 already supports methylation. We cover what "standard dose" actually means — and why higher isn't proven better — in our NAD+ dosage guide.
• •Megadosing NMN/NR, or know your homocysteine is high? TMG is a reasonable, low-cost hedge — but get homocysteine measured rather than guessing, and keep an eye on lipids given the LDL signal¹⁰.
• •Buying a pre-bundled "NMN + TMG" product at a premium? Be skeptical of the framing that the bundle is required. It's the same logic that sells resveratrol alongside NMN — a mechanistic story dressed up as a necessity. We take apart that other popular pairing in NAD+ and resveratrol: do you need the "Sinclair stack"?.

And remember the bigger context: the felt benefits of NMN itself are modest and contested, which is part of why people end up stopping NMN in the first place. Adding TMG doesn't change that underlying picture — it addresses a side-theory, not the main question of whether NMN does much for you.

Bottom line

The TMG-with-NMN stack is built on real biochemistry — clearing nicotinamide does consume methyl groups, and TMG genuinely restores them and lowers homocysteine. But the load-bearing claim, that NMN doses create a methyl deficit you must correct, has never been demonstrated in humans; it's extrapolated from mechanism and high-dose animal data, and the NMN safety trials didn't flag it. For most people on standard doses, TMG is optional — a cheap, plausible hedge with a coherent rationale and a small LDL-cholesterol tradeoff, not a proven necessity. If you take it, take it for the right reasons (high-dose use, elevated homocysteine), not because a bundle told you NMN would otherwise hurt you. For the broader evidence on NAD+ precursors, start with our NAD+ therapy evidence pillar, and compare verified products in our best NAD+ hub.